

|  |
| --- |
|  |
| **https://www.bio.org/sites/default/files/marc%20cochran.jpg**  **Mark Cochran, PhD** Managing Director, Johns Hopkins Healthcare  Mark A. Cochran, PhD, is the Managing Director of Johns Hopkins Healthcare Solutions, a commercialization unit within Johns Hopkins Medicine that expands and manages partnerships with the business world, fostering collaborations among faculty and clinicians to leverage their intellectual assets, and exploring opportunities to share Hopkins-based solutions with external markets. Dr. Cochran’s professional experience spans all levels of the drug discovery, development and healthcare value chain including operational and executive roles in academic, venture capital, pharmaceutical and biotechnology industries. His previous experience includes Bayer Pharmaceuticals, last serving as Vice President of Business Development, Biotechnology, in Berkeley, California; Project Director of Recombinant Factor VIII (Kogenate); and Head of Molecular Biology and Biochemistry in Wuppertal Germany. Dr. Cochran was the CEO and executive director of the Blanchette Rockefeller Neurosciences Institute, which targets advanced research of memory and memory disorders, particularly Alzheimer’s disease. Dr. Cochran’s experience in venture capital includes MDS Capital Corp. and NeuroVentures Capital, as senior managing director. NeuroVentures was a fund specializing in the neurosciences and invested in companies developing drugs, devices and other medical technologies for clinical neuroscience. Dr. Cochran holds a doctorate in microbiology and immunology from Queen’s University, Kingston, Ontario; a master’s in microbiology from the University of Guelph, Ontario, and a bachelor’s degree from the University of Toronto. After he completed a postdoctoral fellowship at the National Institutes of Health, Dr. Cochran co-founded MicroGeneSys, Inc., a Connecticut-based vaccine company (now called Protein Sciences). |